JERSEY CITY, N.J., Nov. 28, 2017 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor conferences:
- The Global Mizuho Investor Conference (MIC) NY at the Lotte New York Palace Hotel on Monday, December 4, 2017.
- The Guggenheim Securities 5th Annual Boston Healthcare Conference at the InterContinental Boston on Wednesday, December 13, 2017.
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company’s lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
MacDougall Biomedical Communications
SOURCE SCYNEXIS, Inc.